You are here

hot flashes

Astellas' Menopause Drug Scores FDA Approval, After Regulatory Setback

Astellas' Menopause Drug Scores FDA Approval, After Regulatory Setback

Yahoo/Benzinga

Flag link:

Cash-strapped Acer sees menopause drug flunk phase 2 trial

Cash-strapped Acer sees menopause drug flunk phase 2 trial

Fierce Biotech

Acer Therapeutics

clinical trials

Flag link:

What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision

Endpoints

patient education

Flag link:

Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Astellas reports Phase III data of fezolinetant for menopause-linked VMS

Clinical Trials Arena

clinical trials

vasomotor symptoms

Flag link:

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Fierce Biotech

clinical trials

Flag link:

Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record

Astellas' menopause drug suffers rare setback as failed Asian trial blots previously pristine record

Fierce Biotech

clinical trials

Flag link:

Astellas’ eyes filings for menopause drug fezolinetant after ph3 win

Astellas’ eyes filings for menopause drug fezolinetant after ph3 win

Pharmaforum

clinical trials

Flag link:

FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish

FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish

Fierce Biotech

clinical trials

Flag link:

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Endpoints

clinical trials

Flag link:

Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market

Bayer inks $425M upfront KaNDy buyout to challenge Astellas for menopause market

Fierce Biotech

KaNDy Therapeutics

Flag link:

Concept Device Designed to Tame Menopausal Hot Flashes

Concept Device Designed to Tame Menopausal Hot Flashes

Medical Devices and Diagnostics Industry

Cambridge Consultants

Flag link:

Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal

Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal

Endpoints

Flag link:

Pfizer: The Menopause Opportunity

Pfizer: The Menopause Opportunity

Seeking Alpha

Ligand Pharmaceuticals

Flag link:

Did Pfizer and Ligand Just Get a New Winning Drug Approved?

Did Pfizer and Ligand Just Get a New Winning Drug Approved?

Wall St. Cheat Sheet

Flag link:

Pfizer, Ligand Win U.S. Approval for Hot Flash Therapy

Pfizer, Ligand Win U.S. Approval for Hot Flash Therapy

Bloomberg

Flag link:

Why Ligand Pharmaceuticals Shares Popped

Why Ligand Pharmaceuticals Shares Popped

Motley Fool

Flag link:

Hisamitsu Wins U.S. Approval for Drug to Ease Hot Flashes

Hisamitsu Wins U.S. Approval for Drug to Ease Hot Flashes

Bloomberg

Flag link:

Hot Flash Drugs Fail to Win FDA Advisers’ Support

Hot Flash Drugs Fail to Win FDA Advisers’ Support

Bloomberg

Flag link:

Menopause Drugs from Depomed, Hisamitsu Offer Benefits

Menopause Drugs from Depomed, Hisamitsu Offer Benefits

Bloomberg

paroxetine mesylate

Flag link:

Serada Approval Presents Big Upside To Depomed

Serada Approval Presents Big Upside To Depomed

Seeking Alpha

Flag link:

Pages